SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that that it will hold an analyst and investor briefing in conjunction with The American Society of Hematology 48th Annual Meeting from 8:00 p.m. to 9:00 p.m. ET on Monday, December 10, 2007.
The event will be webcast and may be accessed in the Event Calendar
page under Investors at http://www.exelixis.com.
-- Michael Morrissey, PhD, President of Research & Development of
-- Gisela Schwab, MD, Senior Vice President & Chief Medical Officer of
-- Ruben Mesa, MD of the Mayo Clinic
An archive of this webcast will be available until 9:00 p.m. PT/12:00 a.m. ET on January 9, 2008. Access numbers for this replay are: 1-888-286-8010 (domestic) and +1-617-801-6888 (international); the replay passcode number is: 63491998.
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.
|SOURCE Exelixis, Inc.|
Copyright©2007 PR Newswire.
All rights reserved